BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Liu YN, Su KY, Chang YL, Wu CT, Liao BC, Hsu CC, Hsu WH, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. Oncologist 2020;25:702-11. [PMID: 32386255 DOI: 10.1634/theoncologist.2020-0088] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Xue F, Xu S, Jiang C, Kang M, Usman M, Zhu L. Case report: Novel junctional sarcoplasmic reticulum protein 1 intergenic region–anaplastic lymphoma kinase fusion in a patient with lung adenocarcinoma responds to alectinib. Front Oncol 2022;12:1019624. [DOI: 10.3389/fonc.2022.1019624] [Reference Citation Analysis]
2 Hsu W, Hsu C, Hsieh M, Tai P, Huang DD, Lee J, Lin C, Chang Y, Yang JC. Spatial Proximity of Tumor Infiltrating Immune Cells Uncovers a Novel Insight in Pulmonary Lymphoepithelial Carcinoma.. [DOI: 10.21203/rs.3.rs-2042378/v1] [Reference Citation Analysis]
3 Chu C, Huang Y, Lee P, Hsu K, Chen K, Su K, Yu S, Tseng J, Yang T, Chang G. Various impacts of driver mutations on the PD-L1 expression of NSCLC. PLoS ONE 2022;17:e0273207. [DOI: 10.1371/journal.pone.0273207] [Reference Citation Analysis]
4 Luo Y, Liang K, Huang H, Shen C, Chiang C, Wang M, Chiou S, Chen Y. State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan. IJMS 2022;23:7037. [DOI: 10.3390/ijms23137037] [Reference Citation Analysis]
5 Zhou Y, Song L, Xu Q, Zeng L, Jiang W, Yang N, Zhang Y. Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib. Lung Cancer 2022;167:58-64. [PMID: 35405360 DOI: 10.1016/j.lungcan.2022.04.002] [Reference Citation Analysis]
6 Li M, Hou X, Chen J, Zhang B, Wang N, Han H, Chen L. ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061). Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Pan Y, Deng C, Qiu Z, Cao C, Wu F. The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer. Front Oncol 2021;11:713530. [PMID: 34660278 DOI: 10.3389/fonc.2021.713530] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
8 Wang H, Chen S, Meng D, Wu C, Zhu J, Jiang M, Ning J, Wu S, Wu L, Li J, Chen B, Zhao S, Li W, Yu J, Fang Q, Zhu J, Zhao W, He Y, Zhou C. Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma. Onco Targets Ther 2021;14:2953-65. [PMID: 33976553 DOI: 10.2147/OTT.S294993] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Christopoulos P, Dietz S, Angeles AK, Rheinheimer S, Kazdal D, Volckmar AL, Janke F, Endris V, Meister M, Kriegsmann M, Zemojtel T, Reck M, Stenzinger A, Thomas M, Sültmann H. Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies. Transl Lung Cancer Res 2021;10:2118-31. [PMID: 34164264 DOI: 10.21037/tlcr-21-32] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
10 Hwang DM, Albaqer T, Santiago RC, Weiss J, Tanguay J, Cabanero M, Leung Y, Pal P, Khan Z, Lau SCM, Sacher A, Torlakovic E, Cheung C, Tsao MS. Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer. J Thorac Oncol 2021;16:1490-500. [PMID: 33915250 DOI: 10.1016/j.jtho.2021.03.028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
11 Bozorgmehr F, Kazdal D, Chung I, Kirchner M, Magios N, Kriegsmann M, Allgäuer M, Klotz LV, Muley T, El Shafie RA, Fischer JR, Faehling M, Stenzinger A, Thomas M, Christopoulos P. De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer. Front Oncol 2021;11:640048. [PMID: 33898315 DOI: 10.3389/fonc.2021.640048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhang Y, Qin Y, Xu H, Yao Q, Gao Y, Feng Y, Ren J. Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib. Pathol Oncol Res 2021;27:637745. [PMID: 34257603 DOI: 10.3389/pore.2021.637745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
13 Elsayed M, Christopoulos P. Therapeutic Sequencing in ALK+ NSCLC. Pharmaceuticals (Basel) 2021;14:80. [PMID: 33494549 DOI: 10.3390/ph14020080] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
14 Chang GC, Yang TY, Chen KC, Hsu KH, Huang YH, Su KY, Yu SL, Tseng JS. ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients. Sci Rep 2020;10:21063. [PMID: 33273548 DOI: 10.1038/s41598-020-78152-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]